Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: Sch-58500, Canji.

D L Barnard1

  • 1Institute for Antiviral Research, Utah State University, 5600 Main Hill, Logan, UT 84322, USA. honery@cc.usu.edu

Current Opinion in Molecular Therapeutics
|March 16, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In vitro and in vivo influenza virus-inhibitory effects of viramidine.

Antiviral research·2005
Same author

Antiviral research - 13th International Conference.

IDrugs : the investigational drugs journal·2005
Same author

Antiviral Research - 15th International Conference. Mega-HAART and tenofovir. 17-21 March 2002, Prague, Czech Republic.

IDrugs : the investigational drugs journal·2004
Same author

In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity.

Antimicrobial agents and chemotherapy·2004
Same author

Fulminant Crohn's colitis after allogeneic stem cell transplantation.

Gut·2003
Same author

Pulmonary complications following bone marrow transplantation.

The British journal of radiology·2003
Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011
Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010
Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010
Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010
Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010
Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010
See all related articles

Sch-58500, a p53 gene therapy, is being investigated for various cancers. It is currently in clinical trials for ovarian, liver, and colorectal cancers, with ongoing research for other cancer types.

Area of Science:

  • Oncology
  • Gene Therapy
  • Cancer Research

Background:

  • Sch-58500 is an investigational gene therapy targeting the p53 tumor suppressor gene.
  • It is being developed by Canji and Schering-Plough for oncological applications.

Purpose of the Study:

  • To evaluate the safety and efficacy of Sch-58500 in patients with various types of cancer.

Main Methods:

  • Sch-58500 is undergoing clinical trials across different phases (I, II, II/III).
  • Trials are focused on specific cancer types including ovarian, hepatocellular, and colorectal cancer metastatic to the liver.

Main Results:

  • Sch-58500 is actively progressing through clinical development for multiple cancer indications.
  • Trial data is being collected to assess therapeutic potential.

Related Experiment Videos

Conclusions:

  • Sch-58500 shows promise as a gene therapy treatment for various cancers.
  • Further clinical evaluation is necessary to establish its role in cancer therapy.